Aveo Oncology's long-troubled tivozanib is unlikely to meet its primary endpoint in a study on colorectal cancer, the company said, sending the biotech back to the drawing board after a high-profile failure in kidney cancer.
When Roche reviewed its big drug pipeline last fall, the pharma giant started its review of an ambitious and wide-ranging set of programs for Alzheimer's disease with a mention of RG7129, an early-stage BACE inhibitor that held the promise of preventing the production of amyloid beta, the toxic protein that figures prominently among the likely causes of Alzheimer's.
Back in January, Jeremy Levin--then riding high as CEO of Teva--didn't think much of the company's program for an immune checkpoint receptor drug dubbed CT-011, or pidilizumab. Now Levin is out, and those checkpoint receptor drugs have emerged as one of the hottest R&D arenas in the industry.
Duke University leads the way among schools with on-campus CROs, and now Oxygen Biotherapeutics has entrusted the institution with handling late-stage studies of its promising heart drug.
Ovarian cancer cells are known to form resistance over time to chemotherapy, limiting the effect that standard cancer drugs can have on the disease. And now, researchers at Rutgers University have developed an RNA method to attack rampant proteins causing the drug resistance, allowing chemotherapy to then take out the cells.
Large compounds can be difficult to push through the skin. Researchers have now developed an ultrasound technique for delivering drugs and breaking down their containers at the desired target.
A team of investigators at the University of Queensland in Australia says it has found an inflammatory protein called PAR2 that builds up in the fat tissue of obese humans and rodents.
The huge sales generated by Prevnar 13 mean Pfizer appears to have the pneumococcal vaccine sector sewn up, but Genocea Biosciences sees an opportunity to disrupt the monopoly. This week, the biotech began a Phase I clinical trial of the vaccine it thinks can unseat Prevnar.
To deliver large proteins past the blood-brain barrier for the treatment of Alzheimer's, researchers have developed a compound that acts as a molecular "crossing guard" for drugs to safely target brain cells and clear plaques believed to cause symptoms of the disease.
Researchers often struggle to validate their cancer biomarker findings due to a lack of reproducible methods to measure predictive proteins. Now, investigators believe they've discovered a way to measure the entire human repertoire of proteins.